Abbott’s medtech sales climbed in Q4 thanks to strength of heart devices
Abbott reported $11.5 billion in sales for the fourth quarter of 2025, a 4.4% increase compared to 2024 that translates to $1.01 per share. While this just barely missed the predictions of some analysts, the company did see its medtech sales grow by 12.3%.
Abbott’s strong medtech performance included significant growth in its diabetes care (14.2%), electrophysiology (13.5%), heart failure (13.2%), rhythm management (13.1%) and structural heart (10.8%) divisions.
One key takeaway from the Q4 earnings call was the fact that sales of Abbott’s continuous glucose monitoring (CGM) devices increased 12% in Q4 and 17% for the entire year.
“This makes the third consecutive year our CGM sales have grown by more than a billion dollars,” Robert B. Ford, Abbott’s chairman and CEO, said during the call. “Our success in CGM continues to be driven by strong underlying market fundamentals, a leading position in cost and scale and an unwavering commitment to market-leading innovation. These factors have led to a continued increase in adoption across all of the various use groups.”
The Navitor TAVR system. Image courtesy of Abbott.
In structural heart, meanwhile, Abbott pointed to double-digit sales growth for the Navitor transcatheter aortic valve replacement (TAVR) system as well as its TriClip and MitraClip devices. That momentum for Navitor is especially critical as Abbott works to catch up to Medtronic and Edwards in the competitive TAVR market. The device also received an expanded CE mark approval in August.
Ford also shared his excitement about two recent regulatory victories for Abbott’s electrophysiology business: the Volt Pulsed Field Ablation System received U.S. Food and Drug Administration approval and the TactiFlex Duo Ablation Catheter, Sensor Enabled secured CE mark approval.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.